ChinaDaily Briefs

Daily Brief China: ZJLD Group, Dali Foods Group, Keep Inc, Shanghai United Imaging Healthcare, Red Star Macalline Group Corp, J&T Global Express, Bosideng International Holdings and more

In today’s briefing:

  • HSCI Index Rebalance Preview and Stock Connect: The Final List for September
  • Merger Arb Mondays (03 Jul) – Dali Foods, Poly Culture, NWS, Yitai, JSR, DDH1, Silk Laser
  • Keep IPO Valuation Analysis: The Minimum Offer Price Looks Attractive. Trading Debut: July 12, 2023
  • CSI300 Index Rebalance Preview: Early Look at Potential Changes in December
  • Hong Kong CEO & Director Dealings: Red Star’s New Controlling Shareholder
  • J&T Global Express Pre-IPO, Part 1: Chinese Express Operation | ‘Haven’t We Met Somewhere Before?’
  • Bosideng (3998 HK): Outlook Stays Promising


HSCI Index Rebalance Preview and Stock Connect: The Final List for September

By Brian Freitas

  • There could be 25 inclusions, including many new listings, to the Hang Seng Composite Index (HSCI) in September. Another 6 stocks are close adds on liquidity and market cap.
  • We see 19 potential deletes and 2 close deletes on market cap, 5 potential deletes on prolonged trading suspension, and 2 close deletes on liquidity.
  • There are 8 potential deletions where holdings via Stock Connect are more than 20% of shares outstanding. There could be some unwinding of positions over the next couple of months.

Merger Arb Mondays (03 Jul) – Dali Foods, Poly Culture, NWS, Yitai, JSR, DDH1, Silk Laser

By Arun George


Keep IPO Valuation Analysis: The Minimum Offer Price Looks Attractive. Trading Debut: July 12, 2023

By Andrei Zakharov

  • Keep Inc., the largest online fitness platform in China, set terms for HK IPO and plans to raise ~HK$667M at the high end of the range at HK$61.46/share. 
  • CICC is leading the offering and Keep Inc (KEEP HK) will trade under the stock code “3650”. The company offers ~10.8M shares at a price range of HK$28.92-HK$61.46.
  • The low end of the range implies an IPO valuation of HK$15B, which looks attractive and is equal to the last round valuation of ~$2B that was led by SoftBank.

CSI300 Index Rebalance Preview: Early Look at Potential Changes in December

By Brian Freitas

  • Two thirds of the way through the review period, we see 14 potential index changes at the December rebalance that will be implemented at the close on 8 December.
  • We estimate a one-way turnover of 1.98% at the December rebalance leading to a one-way trade of CNY 5.32bn.
  • The potential adds have outperformed the potential deletes and the Shanghai Shenzhen CSI 300 Index (SHSZ300 INDEX) over the last five months, though there is some near-term underperformance.

Hong Kong CEO & Director Dealings: Red Star’s New Controlling Shareholder

By David Blennerhassett

  • The data in this insight is collated from the “shareholding disclosure” link on the HKEx website.
  • Often there is a corresponding HKEx announcement on the increase – or decrease – in the shareholding by directors. Or pledging. However, such disclosures are by no means an absolute.
  • The key stock mentioned in this regular insight is Red Star Macalline Group Corp (1528 HK).

J&T Global Express Pre-IPO, Part 1: Chinese Express Operation | ‘Haven’t We Met Somewhere Before?’

By Daniel Hellberg

  • In this insight we look at the development of J&T’s China business over the past few years, including J&T’s purchase of Best Inc’s express operation in late 2021
  • We also compare J&T’s Chinese operation to five listed Chinese express companies in terms of scale, market position, financial performance, and relationships with e-comm platforms
  • Finally, we present a framework for the valuation of J&T’s China business, and offer a list of questions we would ask management as the company prepares for its IPO

Bosideng (3998 HK): Outlook Stays Promising

By Osbert Tang, CFA

  • While having a slow FY23, Bosideng International Holdings (3998 HK) is well-positioned to capture the rebound in down apparel sales growth as pent-up demand is released.  
  • We also expect a recovery in margin, further improvement in channel efficiency and operating leverage from cost control will add to earnings momentum. 
  • Management expects revenue growth will at least sustain at the rate in the last 5 years. The stock’s valuations are cheap when compared with growth outlook and global peers. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars